P180 Immune-Oncology (IO) – Tyrosine Kinase Inhibitor (TKI) or IO-IO as first-line treatment in metastatic renal cell carcinoma: What is better in real-world practice?
O. Stativko, В. Н. Галкин, Т. В. Антонова(First Pavlov State Medical University of St. Petersburg), М. И. Волкова(Yale University), M. Fedyanin, Antonina N. Fedorova, E. Zueva, И. А. Покатаев, М. К. Ибрагимова(National Research Tomsk State University), Albert V. Oskarev, Ya. V. Gridneva, О. В. Синицына(A. N. Nesmeyanov Institute of Organoelement Compounds), E. Tsareva, В. А. Черняев
Cited by 0
Related Papers
“Green” Nanotechnologies: Synthesis of Metal Nanoparticles Using Plants
|Acta Naturae|2014|1.7k
Anthracycline Cardiotoxicity: Prevalence, Pathogenesis and Treatment
|Current Cardiology Reviews|2012|868
Biosynthesis of Stable Iron Oxide Nanoparticles in Aqueous Extracts of <i>Hordeum vulgare</i> and <i>Rumex acetosa</i> Plants
|Langmuir|2014|294
A Genetically Modified Tobacco Mosaic Virus that can Produce Gold Nanoparticles from a Metal Salt Precursor
|Frontiers in Plant Science|2015|76